ECD

Across TCGA pan-cancer cohorts, ECD mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ECD data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ECD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ECD expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD and PDAC are the cancer types where ECD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.879	0.285	.001	16	view →
PDAC	OS	Median	II,III,IV	0.922	0.727	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ECD–LUAD (OS)

Open the LUAD breakdown →